Nephrologic Disorders and COVID-19: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{CMG}} {{AE}} | {{CMG}} {{AE}} {{S.G.}} | ||
==Overview== | ==Overview== | ||
==Complications== | ==Pathophysiology of the Complications in the Nephrologic Disorders== | ||
=== | ==Mechanism of targetting the Nephrologic Disorders== | ||
==Complications in the Nephrologic Disorders== | |||
* | * | ||
===Complication2=== | ===Complication2=== | ||
Revision as of 21:58, 15 June 2020
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]